GFAP and autism: The higher levels of MAP-2, NFP, MBP, MAG, α-synuclein S100B and GFAP (3.2 to 4.8-fold) autoantibodies reported in ASD children warrant further research for developing autoantibodies screening as a biomarker for detection of early autism.